2lberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based Triplet Versus non-platinum se quential doublets in advanced non small-cell lung cancer: a Spanish lung cancer group phase Ⅲ randomized trial[J]. J Clin Oncol, 2003,21 : 3207-3213.
3Bunn P A, Kelly K. New chemotherapeutic agents prolong sur vival and improve quality of life in non small cell lung cancer: a review of the literature and future directions[J]. Clin Cancer Res, 1998, 4(5):1087-1100.
4Socinski M A, Schell M J, Peterman A, et al. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage Ⅲ B/Ⅳ non-small cell lung cancer[J]. J Clin Oncol,2002,20(5):1335.
5Kris M G, Natale R B, Herbst R S, et al. Efficacy of gefitinib, and inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non small-cell lung cancer:a randomized trial[J]. JAMA, 2003,290 : 2149-2158.
6Fukuoks M, Yano S, Giaccone G, et al. Multi institutional randomized phase Ⅱ trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2003, 21:2237-2246.
7Chang A, Parikh P, Thonqprasert S, et al. Gefitinib(IRESSA) in patients of Asian origin with refractory advanced non-small- cell lung cancer: subset analysis from the ISEL study[J]. Thorac Oncol, 2006,1(8) :847-855.
